Human Vaccines Project Scientific Hubs
Vanderbilt University Medical Center
Vanderbilt University Medical Center is one of the top and fastest growing biomedical centers in the country and one of the world’s leading centers for vaccine research with extensive programs in human immunology, cancer immunotherapy, vaccine design and clinical research. Scientifically, Vanderbilt provides institutional leadership for the Human Immunome Program, a large-scale effort fill a major gap in our scientific understanding by determining the parts list of the immune system. Vanderbilt also has extensive experience in the large-scale coordination of clinical studies and serves as the Clinical Coordinating Center for the Human Vaccines Project.
The San Diego Mesa Consortium Scientific Hub
J. Craig Venter Institute
The J. Craig Venter Institute (JCVI) is a nonprofit research institute in La Jolla, Calif., and Rockville, Md., dedicated to the advancement of the science of genomics; the understanding of its implications for society; and communication of those results to the scientific community, the public and policymakers. Founded by J. Craig Venter, Ph.D., the JCVI is home to approximately 200 scientists and staff with expertise in human and evolutionary biology, genetics, bioinformatics/informatics, information technology, high-throughput DNA sequencing, genomic and environmental policy research, and public education in science and science policy. The JCVI is a 501 (c)(3) organization.
La Jolla Institute
La Jolla Institute for Allergy and Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: life without disease®.
The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world’s largest independent, nonprofit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, Calif., and Jupiter, Fla., where its renowned scientists—including two Nobel laureates and 20 members of the National Academy of Science, Engineering or Medicine—work toward their next discoveries. The institute’s graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top 10 of its kind in the nation.
University of California, San Diego
University of California, San Diego is a student-centered, research-focused, service-oriented public institution where a culture of collaboration sparks discoveries that advance society. As part of the Human Vaccines Project, U.C. San Diego researchers and physicians are leveraging the university’s world-class strengths in biomedical research, pharmaceutical sciences, engineering and computer science to produce a detailed understanding of the human immune system and how it responds to vaccines. Participants in the project collaborate across the U.C. San Diego School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences and Jacobs School of Engineering, including the Qualcomm Institute, the U.C. San Diego division of the California Institute for Telecommunications and Information Technology (Calit2), and the Moores Cancer Center at U.C. San Diego Health. Together with the San Diego Supercomputer Center and the J. Craig Venter Institute, U.C. San Diego leads the Project’s Global Bioinformatics Core, a hub that stores and analyzes the genomic and other data generated by research labs and clinical trials participating in the Project.
Human Vaccines Project Product Development Advisors
Aeras is a nonprofit, global biotech organization developing new tuberculosis vaccines for the world, in partnership with other biotech, pharmaceutical and academic organizations. Aeras is primarily funded by The Bill & Melinda Gates Foundation, DFID, GHIT and other parties committed to ending the TB epidemic. The organization also receives support from the U.S. government and through partnerships and collaborations with universities, biotech and pharmaceutical companies around the world.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies, and is committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine. Boehringer Ingelheim currently operates globally with 145 affiliates and more than 47,000 employees. Boehringer Ingelheim’s oncology pipeline encompasses more than ten clinical stage assets being developed in various cancers and tumor types, including multiple new biological and chemical entities and clinical phase projects involving oncolytic viruses, cancer vaccines and T-cell engagers.
GSK is one of the world’s leading vaccine companies, with a comprehensive portfolio of 39 vaccines for infants, adolescents and adults and 15 more in development. The organization employs more than 16,000 people working worldwide to deliver nearly 2 million vaccines every day to people in around 90% of the world’s countries. GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Illumina is improving human health by unlocking the power of the genome. Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function, serving customers in the research, clinical and applied markets. Illumina has developed a comprehensive line of sequencing and array-based products to advance disease research, drug development, and the development of molecular tests in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Janssen Vaccines is committed to developing first-in-class or best-in-class vaccines for some of the world’s most life-threatening infectious diseases. The pathogens the company is developing vaccines against include Ebola, respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), extra-intestinal pathogenic E. coli (ExPEC), methicillin-resistant Staphylococcus aureus (MRSA), polio and influenza.
The organization partners with many of the world’s leading experts, academic and clinical institutions and other pharmaceutical companies for the development of vaccines. It also participates in the Human Vaccines Project. Janssen Vaccines’ partnerships with numerous organizations include the Innovative Medicines Initiative (IMI – European Commission), the National Institutes of Health (NIH), Beth Israel Deaconess Medical Center (BIDMC), the Bill and Melinda Gates Foundation and the Biomedical Advanced Research and Development Authority (BARDA), who contribute in several important projects.
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, U.K., and Mountain View, Calif.
Moderna is a clinical stage developer of messenger RNA (mRNA) therapeutics and vaccines, a new drug technology that directs the body’s cells to produce intracellular or secreted proteins. Moderna is developing mRNA vaccines and therapeutics as a new class of medicines for a wide range of diseases and conditions, including infectious diseases, cancer, liver diseases, cardiovascular diseases and pulmonary diseases. Moderna works through proprietary development and collaborations with strategic partners.
Pfizer Inc. applies science and global resources to bring therapies to people that extend and significantly improve their lives. The company strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Pfizer’s global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high-quality vaccines to meet public-health demand. The company’s heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than 1 million euros in research and development.
Keystone Symposia convenes open, peer-reviewed conferences across a broad range of the life-sciences. The conferences serve as catalysts for the advancement of science by connecting scientists within and across disciplines at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.